Please assess the completion status of the following clinical trial:

Trial Title: Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DMD patients age 7 years and older (and able to complete cardiac MRI without sedation) with preserved left ventricular (LV) systolic function and abnormal heart muscle by late post-gadolinium imaging (LGE)~Exclusion Criteria:~* renal insufficiency (GFR \<40 mL/min/m2)~* non-MR compatible implants (e.g. neurostimulator, AICD)~* severe claustrophobia~* allergy to gadolinium contrast~* prior use of or known allergy to epleronone~* use of potassium-sparing diuretics~* serum potassium level of \>5.0 mmol/L

- Gender: MALE
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- eplerenone (Type: ACTIVE_COMPARATOR): active study drug
- sugar pill (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).